Ardent Health, Inc. (ARDT) Securities Class Action Lawsuit Filed [January 13, 2026]

Introduction to Ardent Health, Inc. (ARDT) Securities Class Action Lawsuit

A securities fraud class action under the Securities Exchange Act of 1934 has been filed against Ardent Health, Inc. (NYSE: ARDT) covering July 18, 2024 through November 12, 2025 (the Class Period). Investors allege the company misrepresented how it evaluated and reserved for accounts receivable collectability and assured the market its professional liability insurance was sufficient for medical malpractice claims. The complaint says Ardent touted “detailed reviews of historical collections” and management-driven write-offs while, in reality, using a 180-day cliff and a revenue recognition that fully reserved accounts at that mark.

On November 12, 2025, Ardent disclosed a sharp revenue reduction tied to revised collectability under a new system, cut guidance, and increased professional liability reserves ($43 million revenue decrease, $57.5 million cut to EBITDA guidance, $54 million increase to professional liability reserves). The stock fell the next day after a 33% stock price decline, and investors claim significant losses.

Ardent Health, Inc. (ARDT) Securities Lawsuit Case Details

Case Name: Postiwala v. Ardent Health, Inc. et al.
Case No.: 3:26-cv-00022
Jurisdiction: U.S. District Court, Middle District of Tennessee
Filed on: January 7, 2026

Ardent Health, Inc. (ARDT) Company Profile

Ardent Health is a holding company (publicly traded on the NYSE as ARDT) whose affiliates operate 30 acute care hospitals and other healthcare facilities and approximately 280 sites of care, with over 1,800 providers in eight mid-sized urban markets across six states, in the healthcare/hospitals sector. Its revenue is primarily net patient service revenue across hospital and ambulatory facilities from third-party payors.

Ardent Health, Inc. (ARDT) Securities Lawsuit Class Period

July 18, 2024–November 12, 2025, inclusive.

Persons and entities that purchased or otherwise acquired Ardent Health securities during the Class Period and were damaged thereby are within the alleged class, and eligible securities include all Ardent Health securities. may be eligible to join the Ardent Health, Inc. (ARDT) class action lawsuit.

Allegations in the Ardent Health, Inc. (ARDT) Securities Class Action Lawsuit

The lawsuit targets Ardent Health, Inc., along with CEO Martin J. Bonick and CFO Alfred Lumsdaine, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the complaint, Defendants told investors that Ardent closely monitored the collectability of its accounts receivable, a key revenue recognition input using “detailed reviews of historical collections” as a primary tool, including hindsight evaluations, and that accounts were written off when management determined they were uncollectible, rather than using a fixed 180-day cliff accounting methodology. They also told the market the company maintained insurance in amounts they believed sufficient for medical malpractice and general liability claims.

The narrative begins with the Registration Statement dated July 17, 2024. On that day, Bonick and Lumsdaine stated Ardent relied on “detailed reviews of historical collections” as a primary source of information as part of its collectability framework and represented that collection procedures continued until management deemed an account uncollectible, at which point it would be written off as part of an active monitoring process. The same filing assured investors that Ardent carried professional malpractice and general liability insurance in sufficient amounts to cover claims.

During this period, management characterized collectability pressures as slower payments rather than nonpayment, as reflected in remarks by Bonick and Lumsdaine, attributing issues to third-party payors and downplaying payor denials. On May 14, 2025, at the Bank of America Global Healthcare Conference, Bonick said, “It’s turning more into a slow pay versus not getting paid,” reinforcing that point, with denials becoming slow pay.

Meanwhile, behind the scenes, investors allege a different reality, including inflated accounts receivable balances. The complaint states Ardent did not primarily rely on detailed hindsight analyses or management determinations; instead, its accounts receivable framework “utilized a 180-day cliff at which time an account became fully reserved”, which investors say overstated revenue. It further alleges Ardent maintained professional malpractice liability insurance for claims arising from its operations and maintained insufficient insurance.

The Truth Emerges

The truth surfaced after market hours on November 12, 2025, and continued on a November 13, 2025 earnings call on the third quarter 2025 results. Ardent revealed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability following a revenue accounting system transition. The company also cut its 2025 EBITDA guidance by $57.5 million and recorded a $54 million increase in professional liability reserves (a 9.6% reduction at the midpoint), including New Mexico claims from 2019-2022.

On the call, Lumsdaine explained that the new system “recognizes reserves earlier in an account’s life cycle,” and contrasted it with Ardent’s prior framework, which “had utilized a 180-day cliff at which time an account became fully reserved.” He also acknowledged “an increasing dynamic year-over-year of increasing premiums, increasing costs in the New Mexico market.” These revelations contradicted earlier statements that emphasized detailed historical collection reviews as the primary basis for collectability and assurances about sufficient professional liability insurance.

Market Reaction

The market reacted immediately to the corrective disclosures. On November 13, 2025, following the after-hours disclosures, Ardent’s NYSE: ARDT stock fell $4.75 per share, or nearly 34%, dropping from $14.05 on November 12, 2025 to close at $9.30, on unusually heavy trading volume.

Next Steps

● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

● The Court will then consider motion for class certification.

● The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Check Eligibility

✓ Free case evaluation
✓ No cost or obligation
✓ See if you qualify

First Name *

Last Name *

Email *

Phone

Estimated Loss

Number of Shares

Purchase Date

Full Name

Submitting this form does not create an attorney-client relationship. Your information is confidential.

Or contact us directly:

(212) 363-7500 [email protected]

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

First Name *

Last Name *

Email *

Full Name

Submitting this form does not create an attorney-client relationship. Your information is confidential.

[email protected] (212) 363-7500

Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

I have reviewed a complaint filed in the action.
I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
My transaction(s) in Ardent Health, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
Within the last 3 years,
I have not sought to serve nor have I served as a class representative in any federal securities fraud case. I have sought to serve as a class representative in
I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Yes. I certify under penalty of perjury that the foregoing is true and correct. Executed this No. I certify under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed this

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Ardent Health, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

I have reviewed the complaint linked in paragraph 1